Pages that link to "Q114455520"
Jump to navigation
Jump to search
The following pages link to Teru Hideshima (Q114455520):
Displaying 50 items.
- Honokiol overcomes conventional drug resistance in human multiple myeloma by induction of caspase-dependent and -independent apoptosis (Q24669763) (← links)
- Azaspirane (N-N-diethyl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) inhibits human multiple myeloma cell growth in the bone marrow milieu in vitro and in vivo (Q24670297) (← links)
- Dual inhibition of canonical and noncanonical NF-κB pathways demonstrates significant antitumor activities in multiple myeloma (Q28271286) (← links)
- Targeting NF-kappaB in Waldenstrom macroglobulinemia (Q28272373) (← links)
- CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. (Q30487339) (← links)
- Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target. (Q30490975) (← links)
- Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma (Q33344746) (← links)
- A phase 2 study of bortezomib in relapsed, refractory myeloma (Q33348702) (← links)
- Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma (Q33386405) (← links)
- Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma (Q33389111) (← links)
- Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple myeloma: a Phase I Multiple Myeloma Research Consortium study (Q33401457) (← links)
- A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma (Q33412684) (← links)
- Outcomes in patients with relapsed or refractory multiple myeloma in a phase I study of everolimus in combination with lenalidomide (Q33414827) (← links)
- Rescue of Hippo coactivator YAP1 triggers DNA damage-induced apoptosis in hematological cancers. (Q33755493) (← links)
- A proto-oncogene BCL6 is up-regulated in the bone marrow microenvironment in multiple myeloma cells (Q33834752) (← links)
- Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma (Q33854012) (← links)
- Phase transitions in human IgG solutions (Q33941043) (← links)
- A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma (Q33944281) (← links)
- Lenalidomide in multiple myeloma: an evidence-based review of its role in therapy (Q33973877) (← links)
- Selective and potent Akt inhibition triggers anti-myeloma activities and enhances fatal endoplasmic reticulum stress induced by proteasome inhibition (Q34075096) (← links)
- PI3K/p110{delta} is a novel therapeutic target in multiple myeloma (Q34124937) (← links)
- New insights into the treatment of multiple myeloma with histone deacetylase inhibitors (Q34224278) (← links)
- Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma (Q34369823) (← links)
- Molecular sequelae of proteasome inhibition in human multiple myeloma cells (Q34393832) (← links)
- Bortezomib in the management of multiple myeloma. (Q34418462) (← links)
- A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib (Q34467271) (← links)
- Thalidomide: emerging role in cancer medicine (Q34511644) (← links)
- NF-kappa B as a therapeutic target in multiple myeloma (Q34521393) (← links)
- Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications (Q34523149) (← links)
- Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model (Q34526773) (← links)
- Novel biologically based therapies for multiple myeloma (Q34996147) (← links)
- Novel therapeutic approaches for multiple myeloma (Q35170935) (← links)
- Halofuginone inhibits multiple myeloma growth in vitro and in vivo and enhances cytotoxicity of conventional and novel agents (Q35552714) (← links)
- Bortezomib (PS-341): A Novel, First-in-Class Proteasome Inhibitor for the Treatment of Multiple Myeloma and Other Cancers (Q35569454) (← links)
- Targeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM) (Q35616060) (← links)
- Targeting proteasome inhibition in hematologic malignancies (Q35648843) (← links)
- Perifosine , an oral, anti-cancer agent and inhibitor of the Akt pathway: mechanistic actions, pharmacodynamics, pharmacokinetics, and clinical activity (Q35741309) (← links)
- An update of novel therapeutic approaches for multiple myeloma (Q35759368) (← links)
- Proteasome inhibition in hematologic malignancies (Q35821602) (← links)
- Combination of a Selective HSP90α/β Inhibitor and a RAS-RAF-MEK-ERK Signaling Pathway Inhibitor Triggers Synergistic Cytotoxicity in Multiple Myeloma Cells (Q35859205) (← links)
- Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis (Q35989478) (← links)
- Proteasome inhibition in the treatment of cancer (Q36012206) (← links)
- Proteasome inhibitor therapy in multiple myeloma (Q36096768) (← links)
- Pathological crystallization of human immunoglobulins (Q36170645) (← links)
- Discovery of selective small-molecule HDAC6 inhibitor for overcoming proteasome inhibitor resistance in multiple myeloma (Q36178810) (← links)
- Proteasome inhibition as a therapeutic strategy for hematologic malignancies (Q36185620) (← links)
- Novel biological therapies for the treatment of multiple myeloma (Q36199182) (← links)
- Identification and validation of novel therapeutic targets for multiple myeloma (Q36254612) (← links)
- Emerging trends in the clinical use of bortezomib in multiple myeloma (Q36289316) (← links)
- Proteasome inhibitors as therapeutics (Q36297878) (← links)